Measurement of body composition by bioelectrical impedance analysis (BIA) is particularly indicated in patients at risk of malnutrition such as those with chronic heart failure. However, there is a fear of potential electromagnetic interferences (EMI) between BIA and implantable cardioverter defibrillators (ICDs) that are often used in this population. Our findings confirm the absence of EMI between ICD and BIA. Body composition assessment by BIA using frequencies from 5-100 kHz can therefore be safely performed without cardiac monitoring in patients equipped with ICDs.
Introduction
Bioelectrical impedance analysis (BIA) is a well-validated, noninvasive, and relatively inexpensive technique to measure body composition and improve nutrition status assessment. 1 A comprehensive nutrition assessment is particularly indicated in patients at risk of malnutrition or weight loss, such as those suffering from chronic diseases including heart failure (HF).
2 About 10% to 15% of patients with chronic HF in New York Heart Association (NYHA) classes II to IV are affected with the most severe form of body wasting named cardiac cachexia, which is a major predictor of poor clinical outcomes. 3, 4 Cardiac cachexia has been defined as ≥5% of body weight loss in ≤12 months or a body mass index (BMI) <20 kg/m 2 in association with several other criteria including low fat-free mass index, which can be measured by BIA. 5 Depending on the country, it is estimated that 25% to 46% of patients with chronic HF followed by HF specialists in Europe have an indication for an implantable cardioverterdefibrillator (ICD) associated or not with cardiac resynchronization therapy (CRT). 6 Therefore, BIA is expected to be performed in a significant number of HF patients equipped with ICDs. However, BIA manufacturers 7 and current nutrition guidelines 2 warn of possible electromagnetic interferences (EMIs) between ICDs and BIA, which is a significant barrier for its use. Indeed, EMI may lead to oversensing, resulting in potentially serious complications including inappropriate 633823P ENXXX10.1177/0148607116633823Journal of Parenteral and Enteral NutritionMeyer et al research-article2016 shocks and inhibition of pacing. To our knowledge, the risk of potential EMI was tested only in a single small study that required further assessment. 8 Therefore, we aimed to prospectively evaluate the potential risk of EMI between BIA and ICDs in a larger number of patients and in a setting where the risk of EMI was experimentally maximized.
Methods

Study Design and Patients
This was a single-center prospective study examining potential EMI between BIA and ICDs. During 3 months, consecutive outpatients scheduled for routine ICD controls at the device clinic of the Geneva University Hospitals were included in the study. Patients who were pacemaker dependent or aged <18 years were excluded from the study. As there were no previous reports of EMI between ICDs and BIA in the literature, we could not calculate a sample size for our study. We tested the hypothesis that there would be no EMI detected between BIA and ICD in a larger population equipped with a wider range of different ICD manufacturers and models compared with previous studies. During ICD interrogation by a cardiologist (L.P.M.), all patients underwent body composition measurements using BIA by a specifically trained PhD student (A.-M.M.). This protocol was approved and accepted as part of a quality control study by the Geneva University Hospitals Ethics Committee. All subjects volunteered for the study.
ICD Interrogation
A standard ICD control was first performed to rule out device dysfunction, and the intracardiac electrogram (EGM) evaluated for baseline noise. Then, the sensitivity levels of the ICD were set to the maximum level while ICD therapies were temporarily inactivated to maximize the risk of EMI with BIA. At each frequency of the BIA current, EGMs were monitored in real time to detect sensed and/or visible EMI (Figure 1 ), and a sample of the tracing was printed for documentation in the patient file. An EMI was defined as the detection of unexpected signals due to the action of the electrical field. The presence of new artifacts visible on the real-time EGM during BIA, but undetected by the device, were also noted. At the end of the experiment, the sensitivity levels were reprogrammed to their initial settings and the ICD therapies were reactivated.
BIA Measurement
After skin cleaning with 70% ethanol, 4 adhesive electrodes (3M Red Dot T; 3M Health Care, Borken, Germany) were placed on the dorsal side of the left hand, left wrist, left foot, and left ankle while the patient was lying supine with palms facing inward. An electrical current of 0.8 mAmp was produced successively at 3 different frequencies (5, 50, and 100 kHz) by a generator/analyzer (Nutriguard M; DataInput, Gmbh, Darmstadt, Germany) during approximately 2 minutes to measure whole-body resistance and reactance. 1 
Data Collection and Statistical Analysis
On the day of the ICD control, each patient was questioned about symptoms for determination of NYHA class and weight changes during the previous year. Weight, height, and vital signs were measured. BMI was calculated as weight (kg) divided by squared height (m 2 ). Information on ICD type, implant date, and indication as well as etiology of heart disease and left ventricular ejection fraction (LVEF) were retrieved from the Geneva University Hospitals electronic medical record.
Descriptive statistics were assessed and results expressed as mean ± standard deviation (SD) for continuous variables and number of patients (%) for categorical variables.
Results
We included 63 patients (54 men) with a mean age of 64.8 ± 14.6 years, mean LVEF of 32.1% ± 16.5%, and mean BMI of 27.9 ± 4.8 kg/m 2 . Primary prevention was the main ICD indication (62%), with a CRT device being implanted in more than half of the patients. Other characteristics of the patients are detailed in Table 1 . The different ICD manufacturers and models are listed in Table 2 . Five major companies were represented: Medtronic (n = 20), Boston Scientific (n = 15), St-Jude (n = 13), Biotronik (n = 11), and Sorin Group (n = 4). Table 3 details the maximum programmable sensitivity for right atrial, right ventricular, and left ventricular electrodes according to each manufacturer.
No EMI were detected by the ICDs during BIA measurements assessed at 3 current frequencies in the 63 participants. Further, no artifacts were visualized during the EGM recordings in any of the ICDs (Figure 1 ; Table 2 ).
Discussion
In this prospective study that included a wide range of different ICD manufacturers and models, we did not detect any interference between BIA and ICDs, even if this risk was experimentally maximized. Our study thus demonstrates that BIA using an electrical current of 0.8 mAmp at frequencies from 5-100 kHz can safely be performed without cardiac monitoring in patients equipped with ICDs. This finding is particularly important for the management of patients with severe chronic HF implanted with ICDs who may present undernutrition or cardiac cachexia and benefit from targeted nutrition interventions.
Electromagnetic fields generated by an electrical current passing through an electrically operated device may produce EMI with ICDs. However, the high frequencies used to assess body composition by BIA (5, 50, 100 kHz) are attenuated by band-pass filters that are centered on the physiological frequencies of endocavitary signals (20-60 Hz). In addition, pacemakers and ICD filters are equipped with ceramic feed-through filters that further attenuate EMI in the 30-MHz to 10-GHz range. These filters provide protection from highfrequency signals generated by devices such as cell phones, microwave ovens, and radars (450 MHz to 12 GHz). 
Buch et al
8 investigated the impact of BIA measurement on ICDs in 20 patients with HF using one type of BIA monitor at 3 different frequencies (5, 50, and 500 kHz) and found no EMI. 8 Our study differs from this previous report in 2 main respects. First, our sample size is >3 times larger, including 29 ICD models from 5 different manufacturers. Second, to maximize the risk of EMI with BIA, we programmed the sensitivity levels of the ICD to the maximum level and placed the BIA electrodes on the left side of the body (as close as possible to the pulse generator). For these reasons, we believe that our study now provides confirmation that there is negligible risk of using BIA in patients equipped with ICDs.
BIA is a well-validated and easy-to-use method to measure body composition as part of a comprehensive nutrition assessment. BIA allows the determination of fat-free mass, body fat, body cell mass, and total body water. The fat-free mass index, calculated as the ratio of fat-free mass to squared height, is now part of the novel definition of cachexia. 5 Cardiac cachexia is associated with a 2-to 3-fold increase in mortality compared with patients without cachexia, which corresponds to a 20% to 40% 1-year mortality. 3, 4 Further studies are urgently needed to better understand the pathophysiology of cardiac cachexia and to develop novel treatments. 4, 11, 12 A comprehensive nutrition assessment using BIA in the most severe HF patients often implanted with ICDs will be important in future trials, some of which are already under way (ClinicalTrials.gov identifier: NCT01864733). Several limitations need to be considered. First, even if the largest to date, our study tested only 63 patients, and our results cannot be generalized to all ICDs available on the market. However, we included different models of the 5 main ICD manufacturers and maximized the risk of EMI in our protocol. Therefore, we believe that the risk of EMI can be considered as negligible for all ICDs and pacemakers (which are equipped with similar filters as ICDs and have lower sensitivity settings). Second, we used a generator producing current frequencies of 5, 50, and 100 kHz and cannot exclude potential EMI with BIA devices that may use other frequency regimens such as pulsing at lower frequencies that may be detected by devices.
Conclusion
To conclude, our study confirms the absence of EMI between BIA and ICD. Body composition assessment by BIA using frequencies from 5-100 kHz can therefore be safely performed without cardiac monitoring in patients equipped with ICDs. Current nutrition guidelines should be updated accordingly.
